Zydus Cadila has received the final approval from US FDA to market Aspirin and extended-release Dipyridamole capsules in the strength of 25 mg/200 mg. The drug is an antiplatelet agent which works in the prevention of excessive blood clotting and is used to reduce the risk of stroke in patients who have had or are at risk of stroke.

The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad. The sales of Aspirin and extended-release Dipyridamole capsules are estimated at USD 198.7 million.


Why is The Government So Bad at Health Care?

 

randox

Digital version